Filing excerpt
In May 2026, Abbott announced it secured CE Mark for Libre® Duo, its dual glucose-ketone biowearable sensor.
sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htmRead the full source
Abbott10-Q: Product launch
Abbott launches new Libre® Duo biowearable in Europe after securing CE Mark in May 2026.
What happened
This includes investment in targeted marketing campaigns, sales force training and enablement, and supply chain logistics to capitalize on the new product approval.
Source
Other signals in this filing (8)
- RestructuringAbbott completes $20.6B acquisition of Exact Sciences, driving massive integration costs.Restructuring
- Capex increaseAbbott completes $20.6B acquisition of Exact Sciences, funded by $20B in new debt.Capex increase
- Quality issueAbbott's $495M legal verdict related to infant formula quality was affirmed on appeal.Quality issue
- Cost reductionSG&A expenses surge 30.3% ($934M) in Q2 due to acquisition integration and higher legal reserves.Cost reduction
- Litigation materialCourt upholds $495M verdict against Abbott in infant formula lawsuit, with more cases pending.Litigation material
- Margin pressureGross margin declined in Q2 2026 due to acquisition costs and inflation.Margin pressure
- International growthAbbott's Medical Devices division sees double-digit growth, led by pacemakers and electrophysiology products.International growth
- Inflation impactGross profit margin squeezed by the "unfavorable impact of higher costs."Inflation impact
Extracted by Autobound
From the Signal API record- Signal
- 10-Q: Product launch
What this signalsFilings often name leadership changes, deals and spending plans.
- Fiscal year end
- 06/30
- Filed
- Jul 28, 2026
More from Abbott
- PatentsAbbott Laboratories's patent output is accelerating: 13 grants in the past year, 2 in the past 30 days.Patents
- RecognitionAbbott declares 411th consecutive quarterly dividendRecognition
- LaunchAbbott Pacemaker Receives FDA ApprovalLaunch
- RedditA veterinary hospital is evaluating the Abbott i-STAT Arterial Blood Gas analyzer, noting its 10% cheaper cartridge cost but expressing concerns about cartridge failure and sampling errors.Reddit
- PartnershipAbbott partners with Sengkang General Hospital to advance early detection of muscle loss in SingaporePartnership
- GlassdoorMultiple reviews cite lack of remote work options or flexibilityGlassdoor
More 10-Q signals at other companies
- SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-Q
- SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-Q
- SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-Q
The full record
From the Signal API recordDetails
- CIK
- 1800
- Accession number
- 0001628280-26-050134
- Timeframe
- Current quarter
- Filing year
- 2026
- Fiscal year
- 0
- Why it matters
- Go-to-market support
- Signal category
- Strategic
Topics and mentions
Technologies
- biowearable sensor
Extraction
- Confidence
- High
- Relevance
- 80%
- Sentiment
- Positive
- Detected
- Aug 4, 2026
- signal_type
sec-10q- signal_subtype
productLaunch
Use this data
Get every 10-Q signal for Abbott and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Abbott this week?”
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/93cadbb1-4aae-42be-bb98-c0c34efe0d65 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbott.com.
{
"signal_id": "93cadbb1-4aae-42be-bb98-c0c34efe0d65",
"signal_type": "sec-10q",
"signal_subtype": "productLaunch",
"detected_at": "2026-08-04T07:07:36.536+00:00",
"company": {
"name": "Abbott",
"domain": "abbott.com"
},
"data": {
"detail": "The launch of the new dual glucose-ketone sensor in the European market creates an immediate need for commercialization support. This includes investment in targeted marketing campaigns, sales force training and enablement, and supply chain logistics to capitalize on the new product approval.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "Abbott launches new Libre® Duo biowearable in Europe after securing CE Mark in May 2026.",
"excerpts": "In May 2026, Abbott announced it secured CE Mark for Libre® Duo, its dual glucose-ketone biowearable sensor.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm",
"filing_date": "2026-07-28",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"technologies_mentioned": [
"biowearable sensor"
]
}
}
curl https://signals.autobound.ai/v1/signals/93cadbb1-4aae-42be-bb98-c0c34efe0d65 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbott.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.